NeoGenomics launches FDA-approved PTEN diagnostic test for prostate cancer
Go back to NeoGenomics launches FDA-approved PTEN diagnostic test for prostate cancer| NEOGENOMICS (NASDAQ: NEO) | Delayed: 14.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.01 | 52 Week High | $9.54 | |||
| Open | $14.01 | 52 Week Low | $5.49 | |||
| Day High | $14.01 | P/E | 350.25 | |||
| Day Low | $14.01 | EPS | $0.04 | |||
| Volume | 56 | |||||
